Population distribution of lifetime risk of ovarian cancer in the United States

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 4, 2015, Pages 671-676

  Pearce, Celeste Leigh ^a   Stram, Daniel O ^a   Ness, Roberta B ^b   Stram, Douglas A ^a   Roman, Lynda D ^a   Templeman, Claire ^a   Lee, Alice W ^a   Menon, Usha ^c   Fasching, Peter A ^d,e   McAlpine, Jessica N ^f   Doherty, Jennifer A ^g   Modugno, Francesmary ^h,i,j   Schildkraut, Joellen M ^k,l   Rossing, Mary Anne ^m,n   Huntsman, David G ^o   Wu, Anna H ^a   Berchuck, Andrew ^l   Pike, Malcolm C ^a,p   Pharoah, Paul D P ^q,r  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g DARTMOUTH MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^j UNIVERSITY OF PITTSBURGH   (United States)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

^l DUKE CANCER INSTITUTE   (United States)

^m Fred Hutchinson Cancer Research Center   (United States)

ⁿ UNIVERSITY OF WASHINGTON   (United States)

^o VANCOUVER GENERAL HOSPITAL   (Canada)

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^q UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^r UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CONTROLLED STUDY; ENDOMETRIOSIS; FAMILY HISTORY; FEMALE; GENETIC RISK; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTIVE USE; OVARY CANCER; POPULATION BASED CASE CONTROL STUDY; POPULATION DISTRIBUTION; PRIORITY JOURNAL; UNITED STATES; UTERINE TUBE LIGATION; VERY ELDERLY; DEMOGRAPHY; LIFE TABLE; OVARIAN NEOPLASMS; RISK FACTOR; UTERINE TUBE STERILIZATION;

ORAL CONTRACEPTIVE AGENT;

CONTRACEPTIVES, ORAL; DEMOGRAPHY; FEMALE; HUMANS; LIFE TABLES; OVARIAN NEOPLASMS; RISK FACTORS; STERILIZATION, TUBAL; UNITED STATES;

EID: 84927948853     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-1128     Document Type: Article

References (21)

1. American Cancer Society. Cancer facts & figures 2013. Atlanta: American Cancer Society; 2013.
2. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 2011;108:18032-7.
3. Pearce CL, Rossing MA, Lee AW, Ness RB, Webb PM, Chenevix-Trench G, et al. Combined and interactive effects of environmental and GWASidentified risk factors in ovarian cancer. Cancer Epidemiol Biomarkers Prev 2013;22:880-90.
4. Bojesen SE, Pooley KA, Johnatty SE, Beesley J,Michailidou K, Tyrer JP, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 2013; 45:371-84, 384e371-372.
5. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010;42:874-9.
6. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun 2013;4:1627.
7. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013;45:362-70, 370e361-362.
8. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, et al. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun 2013;4:1628.
9. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009;41:996-1000.
10. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, et al.Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010;42:880-4.
11. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. J Am Med Assoc 2011;305:2295-303.
12. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-40.
13. Collaborative Group on Epidemiological Studies of Ovarian CBeral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371:303-14.
14. McAlpine JN, Hanley GE,WooMM,Tone AA, Rozenberg N, Swenerton KD, et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014;210:471.e1-11.
15. Lo-CiganicWH, Zgibor JC, Bunker CH, Moysich KB, Edwards RP, Ness RB. Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology 2012;23: 311-9.
16. Moorman PG, Calingaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, et al. Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol 2008;167:1059-69.
17. Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH. Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril 2004;82:186-95.
18. Wu AH, Pearce CL, Tseng CC, Templeman C, Pike MC. Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int J Cancer 2009;124:1409-15.
19. Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullumM, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol 2013;121:14-24.
20. Sieh W, Salvador S,McGuire V, Weber RP, Terry KL, Rossing MA, et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of casecontrol studies. Int J Epidemiol 2013;42:579-89.
21. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007;19:3-9.